PerkinElmer, a global leader in life science research, drug discovery and cellular science, today announced the launch of its specialized GMP (Good Manufacturing Practice) Services for radiosynthesis of compounds for ADME (Absorption, Distribution, Metabolism and Excretion) research studies. PerkinElmer’s GMP Radiosynthesis Services provide advanced expertise for the manufacturing of radiolabeled compounds to help pharmaceutical, biotechnology and contract research organizations (CROs) accelerate drug development outcomes.

As the cost of drug development continues to rise, the early evaluation of drug candidates and success of ADME studies becomes increasingly important. PerkinElmer’s GMP Radiosynthesis Services are designed to support these critical preclinical drug development efforts by assuring GMP* compliance and quality of service to help research groups meet their aggressive deadlines with robust results. The Service tags target drug candidates with radioactive materials to help research groups discover what happens to these compounds in the human body by measuring and monitoring the radioactivity.

“We are very pleased to announce the launch of PerkinElmer’s GMP Radiosynthesis Services to help our customers achieve better early drug development outcomes,” said Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer. “PerkinElmer is one of the few providers of this radioactive service, and our deep expertise in this unique area dates back more than fifty years. Our GMP Services team uniquely combines technical expertise in the manufacture of radiolabeled compounds with the industry knowledge required to meet our clients’ exacting regulatory and documentation requirements.”

PerkinElmer’s GMP Radiosynthesis Services support team leverages more than five decades of radioactive materials expertise backed by GMP capabilities, including a new state-of-the-art GMP Radiosynthesis facility and a vast compound catalog for screening experimentation. PerkinElmer is the premier manufacturer of custom GMP radiolabeled compounds in the U.S. Compounds are routinely 98-plus percent pure, and are provided with 100 percent on-time delivery.

PerkinElmer’s GMP Radiosynthesis Services include:

— GMP synthesis for Phase I studies

— Non-GMP synthesis for preclinical animal studies

— Radiochemical stability testing

— Special packaging using NRC-approved PerkinElmer materials

— Analytical services

— Worldwide shipping

PerkinElmer’s Bio-discovery business is part of the PerkinElmer Life & Analytical Sciences division and provides the most comprehensive offering of enabling technologies and services including biochemistry, detection systems, cell imaging, and liquid handling to accelerate life sciences research, from drug discovery to academic research.

* GMP consistent with ICH Q7A, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, August, 2001, Section 19, API’s for Use in Clinical Trials.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has approximately 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.